Category Prostate Cancer

26
Jan

Brachytherapy reduced death rates in high-risk prostate cancer patients, study finds

Brachytherapy for high-risk prostate cancers patients has historically been considered a less effective modality, but a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests otherwise. A population-based analysis looking at almost 13,000 cases revealed that men who received brachytherapy alone or in combination with external beam radiation therapy (EBRT) had …

16
Jan

New Clinical Trial: Cabazitaxel with Radiation and Hormone Therapy May Improve Prostate Cancer Survival

Jefferson’s Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind multimodality approach could improve disease control and eventually survival for locally advanced prostate cancer patients. The single-center, open-label, non-randomized Phase I study of weekly Cabazitaxel …

14
Oct

Ulrich Rodeck receives Ben Franklin-PCF Creativity Award

Ulrich Rodeck, M.D., Ph.D., a professor in the Department of Dermatology and Cutaneous Biology, at Jefferson Medical College, Thomas Jefferson University, received the Ben Franklin-Prostate Cancer Foundation Creativity award for his work in improving the therapeutic window of radiation therapy for prostate cancer. Radiation therapy of locally advanced prostate cancer is associated with severe toxicity …

29
Sep

Kimmel Cancer Center at Jefferson Celebrates 20 Years of Patient Care and Cancer Discovery

From October forward, the Kimmel Cancer Center at Jefferson (KCC), a National Cancer Institute-designated cancer center, is celebrating 20 years of service to the community and the groundbreaking cancer research from the scientists and physicians who’ve provided an invaluable contribution to medical science and healthcare. “This is truly a milestone for the Kimmel Cancer Center—it’s …

29
Aug

Robert B. Den, M.D., Joins the Department of Radiation Oncology at Jefferson

Radiation oncologist Robert B. Den, M.D., recently joined Thomas Jefferson University Hospital as an attending physician, and was also named an assistant professor at Jefferson Medical College of Thomas Jefferson University in the Department of Radiation Oncology. Dr. Den is a clinical scientist who specializes in the treatment of prostate cancer, combining his laboratory research …

5
Jul

Radiation after prostate removal is cost-effective, but less likely to be recommended by urologists

Receiving radiation therapy immediately after a radical prostatectomy is a cost-effective treatment for prostate cancer patients when compared with waiting and acting on elevated prostate-specific antigen (PSA) levels, according to a new study by researchers at Thomas Jefferson University and Hospital. What’s more, a separate, but related study, found that urologists were less likely than …

1
Jun

Dr. Karen Knudsen Receives Ron Ross Award

See the Award Announcement for more information about the Award and its latest recipient. The following was abstracted from the announcement. Dr. Karen Knudsen of the Kimmel Cancer Center received the Ron Ross Award at the 5th Pacific Rim Breast and Prostate Cancer Meeting, held in Kingscliff, Australia, May 3-7, 2011. Dr. Ron Ross was …

1
Jun

KCC Research: Cancer Cells Accelerate Aging & Inflammation in Body to Drive Tumor Growth

Researchers at the Kimmel Cancer Center at Jefferson have shed new light on the longstanding conundrum about what makes a tumor grow—and how to make it stop.  Interestingly, cancer cells accelerate the aging of nearby connective tissue cells to cause inflammation, which ultimately provides “fuel” for the tumor to grow and even metastasize. This revealing …

13
Apr

Jefferson Doctors Strengthen Case for High-Dose Radiotherapy Technique After Radical Prostatectomy

A widely-available yet expensive radiotherapy technique used to treat prostate cancer patients after surgery has promising benefits—higher dose and less damage to the rectum and bladder—compared to a less precise technique, Thomas Jefferson University researchers document for the first time in a new study published in Practical Radiation Oncology. A team of radiation oncologists and …

22
Feb

“Longevity” Protein SIRT1 May Ward Off Precursor to Prostate Cancer

Researchers from the Kimmel Cancer Center at Jefferson and two other institutions have discovered new evidence that suggests the “longevity” protein SIRT1, known for its life-spanning effects in different species, can inhibit the development of a known precursor to prostate cancer, prostatic intraepithelial neoplasia (PIN). “Prostate cancer is one of the malignancies that has a …

21
Feb

Dr. Leonard Gomella co-chairs ASCO GU in Orlando

Dr. Leonard G. Gomella, chair of the Department of Urology and director of Clinical Affairs at the Kimmel Cancer Center at Jefferson, co-chaired the American Society of Clinical Oncology (ASCO) 2011 Genitourinary (GU) Cancers Symposium meeting in Orlando on Feb. 17 though Feb. 19. The “2011 Genitourinary Cancers Symposium: An Evidence-based Multidisciplinary Approach,” was a …

15
Feb

Researchers Say Stress Fuels Cancer Growth, Provide Genetic Evidence That Antioxidants Can Help Treat It

Researchers from Jefferson’s Kimmel Cancer Center have genetic evidence suggesting the antioxidant drugs currently used to treat lung disease, malaria and even the common cold can also help prevent and treat cancers because they fight against mitochondrial oxidative stress—a culprit in driving tumor growth. For the first time, the researchers show that loss of the …

20
Dec

2010 Men’s Event Recap

On Tuesday, November, 16th 2010, the Kimmel Cancer Center at Jefferson held the Second Annual Men’s Event at the Prime Rib Restaurant in Philadelphia. The Men’s Event was emceed by Comedian Joe Piscopo. The inaugural Kimmel Cancer Center Men’s Event “Man of the Year Award”  was awarded to Mr. Kenneth Gamble, a world-renowned Grammy winning …

24
Nov

Loss of the retinoblastoma tumor suppressor pushes prostate cancer into lethal stage, say Kimmel Cancer Center researchers

Their study, the first to uncover a new role for this powerful gene, may lead to clinical “barcoding” of a patient’s prostate cancer to help direct therapy (PHILADELPHIA) – The retinoblastoma tumor suppressor gene (Rb), long thought to protect cells against cancer development, appears to play a very different role in prostate cancer, say scientists …

23
Sep

The Ramblewood Country Club Hosted John Runyan’s 2010 “Score For The Cure” Golf Tournament

The Ramblewood  Country Club in Mount Laurel, NJ hosted John Runyan’s 2010 “Score For The Cure” Golf Tournament on September 21st 2010. The proceeds benefited the Kimmel Cancer Center of Jefferson. Dietz & Watson was the Title Sponsor of the event. This  marks the 6th year of the event which has raised nearly $1,000,000 in …

23
Aug

The Ace Club will host the Prostate Cancer Foundation’s 8th Annual Philadelphia Prostate Cancer Fundraiser

The Ace Club will host the Prostate Cancer Foundation’s 8th Annual Philadelphia Prostate Cancer Fundraiser. Clay Hamlin and Neal Rodin invite you to join Michael Milken at the 8th Annual Philadelphia Prostate Cancer Fundraiser.

13
Aug

Free Prostate Cancer Screenings

The Kimmel Cancer Center at Jefferson and Prostate Health International’s Gary Papa Run are offering free prostate screenings as part of a research program. Prostate cancer is the second leading cause of cancer death among men. Screening is important because prostate cancer shows no symptoms in its earliest stages.

24
May

Scientists Find Protein Spurs Spread of Prostate Cancer

Researchers from the Kimmel Cancer Center at Jefferson have found that Stat5, a signaling protein previously found to be key to survival of prostate cancer, is also involved in metastasis. Their study, published in the online edition of Endocrine-Related Cancer, demonstrates in both laboratory and animal models that nuclear Stat5 over-expression leads to a deadly …

19
May

Jefferson Scientists Unlock Secret to Powerful Tumor Suppressor That Can Reverse Cancer Progression

Researchers at the Kimmel Cancer Center at Jefferson have discovered how a powerful tumor suppressor called DACH1 works – a finding that explains why restoring its lost function in cancer cells pushes them to become normal again. In the March 29 online early edition of the Proceedings of the National Academy of Sciences (PNAS), the …

2
Apr

Dr. Leonard G. Gomella Studies the Effect of Dutasteride on the Risk of Prostate Cancer

Dr. Leonard G. Gomella and colleagues conducted a landmark international randomized, double-blind, placebo-controlled, parallel-group multi-center clinical trial to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease. Over the course of the 4-year study period, dutasteride reduced the risk of …

Page 3 of 4